AryoGen Pharmed Co.
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
50%
6 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
Role: lead
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
Role: lead
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
Role: lead
AryoTrust® (Trastuzumab) Safety Study
Role: lead
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
Role: lead
Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Role: lead
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Role: lead
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors
Role: lead
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
Role: lead
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
Role: lead
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
Role: lead
Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects
Role: lead
All 12 trials loaded